Spots Global Cancer Trial Database for Efficacy and Safety of Subsequent Cisplatin and Docetaxel in Ovarian Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Efficacy and Safety of Subsequent Cisplatin and Docetaxel in Ovarian Cancer
Official Title: The Evaluation of Efficacy and Safety of Subsequent Cisplatin and Docetaxel Regimen In The First Line Treatment of Advanced Epithelial Ovarian Cancer
Study ID: NCT00772863
Conditions
Interventions
Study Description
Brief Summary: The purpose of this study is to assess the efficacy and the safety of the treatment.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: FEMALE
Healthy Volunteers: No
Locations
Sanofi aventis administrative office, Istanbul, , Turkey
Contact Details
Name: Edibe Taylan, MD
Affiliation: Sanofi
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
